KRYSHealthcare · BiotechnologyThe 11 Wall Street analysts covering Krystal Biotech, Inc. hold a median 12-month price target of $389 — +13.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Krystal Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (29): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KRYS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +13.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | RBC Capital | Initiates | Outperform | $400 |
| 4 Aug 2026 | Citigroup | Maintains | Buy | $378 → $386 |
| 4 Aug 2026 | Citigroup | Maintains | Buy | — |
| 14 July 2026 | B of A Securities | Maintains | Buy | $364 → $396 |
| 14 July 2026 | B of A Securities | Maintains | Buy | — |
| 18 June 2026 | TD Cowen | Maintains | Buy | — |
| 16 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Buy | — |
| 5 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 25 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 18 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 18 Feb 2026 | Citigroup | Maintains | Buy | — |
| 17 Feb 2026 | Jefferies | Maintains | Buy | — |
| 2 Feb 2026 | Goldman Sachs | Maintains | Buy | — |
| 22 Jan 2026 | B of A Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRYS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Krystal Biotech, Inc. returned +127.0% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 18% of US stocks
Cheaper than 9% of US stocks
Cheaper than 13% of US stocks
Cheaper than 5% of US stocks
Higher than 74% of US stocks
Higher than 72% of US stocks
Higher than 98% of US stocks
Higher than 96% of US stocks
Higher than 97% of US stocks
Higher than 81% of US stocks
Higher than 91% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Krystal Biotech, Inc. has a market value of $10.3B and an enterprise value of $9.4B.
Revenue in the twelve months to 30 June 2026: $440.5M. The latest quarter grew 24.1% year on year.
Net income over the same four quarters: $241.5M, a 54.8% net margin.
Diluted earnings per share, trailing twelve months: $7.98.
Free cash flow in the twelve months to 30 June 2026: $257.8M.
Trailing P/E: 43.5×; forward P/E: 36.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Krystal Biotech, Inc. employs 295 people — $1.5M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Krystal Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Krystal Biotech reported second-quarter results that beat EPS estimates, with Vyjuvek sales rising 24%. Despite that beat and broader access, global expansion and pipeline progress, its shares fell.
Why it matters — A KRYS watcher would track these results because they pair an earnings and sales beat with a share decline, leaving ongoing pipeline and commercial progress as the key focus.
Krystal Biotech, Inc. published its Q2 2026 earnings call transcript. The transcript covers the company's quarterly financial and business discussion.
Why it matters — A KRYS watcher would review the transcript for management's commentary on the company's quarterly performance.
Investors Business Daily reports that stocks including Eli Lilly, Twilio, and Hinge Health face a key test as they move ahead of earnings reports, advising investors to pay attention to important chart lines. Krystal Biotech (KRYS) is not mentioned in this item.
Why it matters — KRYS is not referenced in this item, so it offers no direct news about the company for Krystal Biotech watchers.
Krystal Biotech reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period. The increase came as the company expanded treatment access for patients with dystrophic epidermolysis bullosa (DEB) in the United States and overseas.
Why it matters — The 24% year-over-year revenue growth and expanding DEB treatment access indicate continued commercial traction for Krystal Biotech’s VYJUVEK.
Krystal Biotech reported Q2 earnings of $1.79 per share, surpassing the Zacks Consensus Estimate of $1.70 per share and up from $1.29 per share in the same quarter last year.
Why it matters — The earnings beat and year-over-year growth signal continued financial outperformance, which KRYS watchers may view as a sign of strong operational execution.
The 11 Wall Street analysts covering Krystal Biotech, Inc. have a median 12-month price target of $389, with estimates ranging from $284 to $474. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Krystal Biotech, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Krystal Biotech, Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Krystal Biotech, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +13.9% from the last close, and Ticker Nerd's factor model ranks Krystal Biotech, Inc. 79 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Krystal Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $284 to $474 over the next 12 months.
Krystal Biotech, Inc. returned +127.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Krystal Biotech Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for severe, life-threatening, and rare diseases with high unmet medical needs.
The most recent item we track (Zacks Investment Research, 4 Aug 2026): "Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus". Krystal Biotech reported second-quarter results that beat EPS estimates, with Vyjuvek sales rising 24%. Despite that beat and broader access, global expansion and pipeline progress, its shares fell.
Krystal Biotech Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for severe, life-threatening, and rare diseases with high unmet medical needs. The company specializes in redosable gene therapies built on a proprietary herpes simplex virus type 1 (HSV-1) vector platform, enabling targeted delivery of therapeutic genes to skin and other tissues. Krystal Biotech’s core area of impact is specialty dermatology, where it offers Vyjuvek, a prescription gene therapy for dystrophic epidermolysis bullosa, a rare inherited skin disorder characterized by extreme fragility and chronic wounds. Beyond dermatology, the company is advancing a pipeline that extends its platform into oncology and respiratory indications, aiming to address complex solid tumors and genetic lung diseases through localized gene delivery. Krystal Biotech operates as a fully integrated enterprise, with in-house CGMP manufacturing facilities to support discovery, clinical development, and commercial supply of its therapies. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a distinct role in the biotechnology market as a leader in redosable gene therapy for rare conditions.
CEO Mr. Krish S. Krishnan M.B.A., M.S. · 295 employees · United States · https://www.krystalbio.com
